SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as investors weigh its potential as a leading privacy-focused asset against broader market volatility and regulatory scrutiny. The community remains deeply divided, with some betting on its long-term value due to increasing interest in shielded transactions, while others remain skeptical, often criticizing it as a volatile asset amidst broader cryptocurrency market fluctuations.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401jK is gaining traction as a community-driven "Resist & Retire" movement, with investors actively discussing its role as a satirical alternative to traditional retirement plans. The community is focused on long-term accumulation, IRL raids, and educational content, positioning the token as a narrative-led project that aims to challenge systemic financial corruption.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is generating significant momentum as the community focuses on reclaiming and restoring the original internet culture associated with classic rage comics. Enthusiasts are actively highlighting their efforts to build on Solana, positioning the project as a multi-cycle, memetic powerhouse that prioritizes authentic culture over transient market trends.

WorldFinancial

WorldFinancial (WLFI) is trending as investors debate the impact of high-profile political ties and an upcoming crypto forum at Mar-a-Lago amid intense scrutiny from government probes into foreign investment deals. The community remains deeply divided, with bulls betting on institutional adoption and a short squeeze, while bears highlight risks related to token dilution, regulatory investigations, and skepticism over the project's long-term utility.

iShares Trust - iShares Core S&P 500 ETF

iShares Core S&P 500 ETF

Investors are closely monitoring IVV and the broader S&P 500 as markets contend with lingering concerns over rising geopolitical tensions and potential economic volatility. The community remains focused on long-term resilience and dividend strategies, while debates continue over whether to buy current dips or brace for deeper corrections amidst uncertainty.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Investors are actively debating Ethereum's role as a long-term hedge against monetary debasement and a settlement layer for tokenized assets, while community sentiment remains split over recent whale selling and price volatility. Discussions are heavily focused on the impact of shifting liquidity conditions, regulatory clarity, and the potential for a technical breakout if the asset sustains key support levels.

United States Gasoline Fund LP. - United States Gasoline Fund LP

United States Gasoline Fund LP

United States Gasoline Fund (UGA) is trending as energy markets react to tightened global supply, the ongoing blockade of the Strait of Hormuz, and subsequent warnings of a measurable supply shock affecting fuel prices. Investors are closely monitoring gasoline futures and retail pump prices as community discussion shifts toward long-term inflation concerns, the impact of war on global shipping, and the broader economic consequences of sustained high energy costs.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinal Infrastructure Group is attracting attention due to significant insider buying and positive analyst revisions, fueling a steady upward momentum. Investors are actively discussing its status as a 'slo-mo' IPO, noting the stock's resilient, gradual grind higher despite currently flying under the broader market radar.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the semiconductor sector rides a massive wave of AI infrastructure demand, with investors focused on the critical role of advanced packaging as a supply chain bottleneck. Community discussion is dominated by the company's strategic expansion of its Arizona campus, its status as a key domestic partner for major chipmakers, and its position as an overlooked "pick and shovel" play in the current semiconductor super cycle.

TOSHI

Toshi is capturing attention as community members debate its potential for a turnaround while closely monitoring Bitcoin's price action and broader market volatility. Investors are actively discussing the coin's technical consolidation and the anticipation of a meme-driven rally, with many adopting a patient accumulation strategy during this period of price discovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

SG Americas Securities LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 74.4% during the 4th quarter, according to the company in its most recent...

Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 54.9% during the fourth quarter, according to its most recent Form 13F filing with the...

How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval

LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.

Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% - What's Next?

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% - Still a Buy...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Exchange Traded Concepts LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 55.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,981 shares of the company's stock after...

What's Going On With Structure Therapeutics Stock On Wednesday?

Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.read more...

<ul class="summary-bullets"><li>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss.</li><li>Structure Therapeutics expects to initiate late-stage clinical development of its experimental drug Aleniglipron in the second half of 2026.</li><li>According to data from Koyfin, GPCR stock carries a 12-month average target of $109, while VKTX stock carries a 12-month average target of $92.72.</li></ul>Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are capturing intense investor attention as obesity treatments are increasingly deemed the largest growth engine in the U.S. pharmaceutical industry.Eli Lilly (LLY) and Novo Nordisk (NVO) currently dominate the current obesity drug market. Smaller firms Viking and Structure are both developing drugs for obesity even as bigger names like Pfizer (PFE) and AstraZeneca (AZN) also seek to enter the competition ring.<h2 class="st-heading-2">Viking, Structure’s Obesity Pipelines</h2>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said.The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.Meanwhile, Structure said earlier this month that its experimental drug Aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks in a mid-stage trial. The company now expects to initiate late-stage clinical development of the drug in the second half of 2026.The company also has other investigational obesity drugs called ACCG-2671 and ANPA-0073 currently in early stage studies. &nbsp;<h2 class="st-heading-2">Who Offers Better Upside?</h2>According to data from Koyfin, GPCR carries a 12-month average target of $109, implying a 147.95% upside potential from its last close. The stock holds a consensus analyst rating of 'Strong Buy', with 15 analysts rating the stock ‘Buy’ or higher while one rates it a ‘Hold’.Meanwhile, VKTX carries a 12-month average target of $92.72, representing a 209.80% upside from current levels. The stock also holds a consensus 'Strong Buy' rating, with 17 analysts rating it ‘Buy’ or higher while two hate it ‘Hold’.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment toward VKTX stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Meanwhile, sentiment toward GPCR stock stayed within the ‘bearish’ territory, while message volume fell from ‘normal’ to ‘low’ levels. &nbsp;<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has climbed 24% this year, while <a href="https://stocktwits.com/symbol/GPCR">GPCR</a> surged 154%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-doubles-down-on-heavy-duty-gas-trucks-amid-massive-ev-writedowns-report/cZERzvHRINm">GM Doubles Down On Heavy-Duty Gas Trucks Amid Massive EV Writedowns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

VKTX Vs. GPCR: Which Obesity Drug Developer Does Wall Street See With The Bigger Upside?

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 

Equity

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 


Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Current Price	$54.51
Prev Close	$55.14
Open	$55.11
Dividend Yield	0.00%
50-Day Moving Average	$62.22
Beta	0.89
Avg. Volume	1.02M
PE Ratio	-22.18

52-Week High	$94.90
52-Week Low	$15.80
Market Capitalization	$3.86B
EPS (Annual)	-$2.39
Price to Book	2.55
Revenue Per Employee	$0.00

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR